Could serum total cortisol level at admission predict mortality due to coronavirus disease 2019 in the intensive care unit? A prospective study

Sao Paulo Med J. 2021 Jul-Aug;139(4):398-404. doi: 10.1590/1516-3180.2020.0722.R1.2302021.

Abstract

Background: Critical diseases usually cause hypercortisolemia via activation of the hypothalamic-pituitary-adrenal axis.

Objectives: To investigate the relationship between serum total cortisol level and mortality among coronavirus disease 2019 (COVID-19) patients in the intensive care unit (ICU), at the time of their admission.

Design and setting: Prospective study developed in a pandemic hospital in the city of Şırnak, Turkey.

Methods: We compared the serum total cortisol levels of 285 patients (141 COVID-19-negative patients and 144 COVID-19-positive patients) followed up in the ICU.

Results: The median cortisol level of COVID-19-positive patients was higher than that of COVID-19 negative patients (21.84 μg/dl versus 16.47 μg/dl; P < 0.001). In multivariate logistic regression analysis, mortality was associated with higher cortisol level (odds ratio: 1.20; 95% confidence interval: 1.08-1.35; P = 0.001). The cortisol cutoff point was 31 μg/dl (855 nmol/l) for predicting mortality among COVID-19-positive patients (area under the curve 0.932; sensitivity 59%; and specificity 95%). Among the COVID-19 positive patients with cortisol level ≤ 31 μg/dl (79%; 114 patients), the median survival was higher than among those with cortisol level > 31 μg/dl (21%; 30 patients) (32 days versus 19 days; log-rank test P < 0.001).

Conclusion: Very high cortisol levels are associated with severe illness and increased risk of death, among COVID-19 patients in the ICU.

MeSH terms

  • COVID-19*
  • Humans
  • Hydrocortisone*
  • Hypothalamo-Hypophyseal System
  • Intensive Care Units
  • Pituitary-Adrenal System
  • Prospective Studies
  • SARS-CoV-2

Substances

  • Hydrocortisone